Skip to main content
. 2019 Apr 26;7:e6716. doi: 10.7717/peerj.6716

Figure 3. Effects of CVS pretreatment on the expression of critical proteins.

Figure 3

(A–H) Effects of CVS on the expression of p-AKT (A, B), p-BAD (C, D), p-MDM2 (E, F), and p53 (G, H) in activated Aβ25−35-treated PC12 cells. Each experiment was completed with a minimum of five replicates. Statistical significance is presented as; ##p < 0.001 versus Ctrl; * italicp < 0.01, **p < 0.001 versus Aβ. Abbreviations: Aβ, Aβ25−35 treatment group; AKT, AKT serine/threonine kinase; BAD, BCL2 associated agonist of cell death; C, curcumin and Aβ25−35 treatment group; Ctrl, control group; CV, curcumin, vorinostat and Aβ25−35 treatment group; CVS, curcumin, vorinostat, silibinin and Aβ25−35 treatment group; MDM2, MDM2 proto-oncogene 2; p53, tumor protein p53.